Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

Factors
accessory, 877
granulocyte-macrophage colony-stimulating, IgM-RF in bone marrow cells in RA and, 384
growth, 413, 669, 877, 960
insulin-like growth 1, 413
latent transcription, 877
mammary gland, 877
nuclear κB, 1762
transcription, 1762
transforming growth β, 306, 499, 669
tumor necrosis, 211, 1531
tumor necrosis α, 29, 105, 151, 164, 406, 499, 525, 601, 669
Fallon Community Health Plan, HMO, incidence of OA in, 1134
Familial OA, COL2A1 gene mutation in, 999
Family involvement
guidelines for medical management of OA and, 1535
impact of musculoskeletal conditions and, 1351
in work disability in RA, 1630
Farr assay, to study antigen-based heteropolymers, 190
Fas/APO-1, serum soluble, autoimmune disease and, 1738
Fas/APO-1/CD95, soluble, in SLE and JRA, 1735
Fasciitis, eosinophilic, in carpal tunnel syndrome due to T cell lymphomas, 1707
Fat, bone marrow, in inflammatory response in sickled erythrocytes, 1349
Fatal adult respiratory syndrome, in PM with anti-Jo-1 antibody, 1519
Fatal pulmonary complication of lupus pregnancy, 710
Fatigue
chronic fatigue syndrome, 638, 1363
every-other-week MTX in RA and, 601
in SLE, 826, 1475
Fatty acids, [gq], high-dose fish oil, NSAID and, in RA, 1107
Fc binding sites, immunosuppressive drugs during pregnancy and, 1722
Fc receptors
IIa, in renal disease in SLE, 1832
γ I (Fcgr1) gene, cytokines and, 877
IgG receptors in autoimmune disease and, 306
Fecal occult blood, NSAID, gastrointestinal tract and, 5
Federated Council of Internal Medicine Task Force on Work Force Reform, rheumatology and, 451
Fee-for-service medical care, rheumatology and, 451
Feet, in gouty arthritis in AIDS, 570
Felty's syndrome, hematology of large granular lymphocytes and, 1252
Femoral condyle
in OA, 660, 1290
proteoglycans and, in articular cartilage, 660
in RA, 660
Femoral head deformity and femoral neck, in bone mineral density in hip OA, 907
Femoral neck, osteoporosis in RA and, 806
Femoropatellar groove cartilage, stromelysin degradation of, 1678
Femur in OA
distal, in CPPD synovitis in rabbits, 201
knee in athletes and, 539
Fertility, immunosuppressive drugs during pregnancy and, 1722
Fetal calf serum, to study RF B cell in RA, 1771
Fetus
immunosuppressive drugs during pregnancy and, 1722
loss of, in bone marrow transplantation in antiphospholipid syndrome, 115
monoclonal antibodies in detection of biochemical markers of arthritis and, 655
proteoglycans in, articular cartilage in OA and RA and, 660
Fever
in cutaneous PAN associated with Crohn's disease and atrial myxoma, 1161
in RA, 1177, 1187, 1581, 1589
18F-fluoro-2-deoxyglucose, MRI, PET and, in RA, 819
Fibers, in peripheral neuropathy with necrotizing vasculitis in RA, 1618
Fibrillar collagen, degradation of, elastin and, in SSc, 517
Fibrin, somatostatin in experimental arthritis and, 1687
Fibroblast-like cells
activation markers of RA synovial membrane and, 1346
rheumatoid synovial, EDA-containing fibronectin in, 678
Fibroblasts
adhesion molecules in disease activity in SSc and, 184
Chlamydia trachomatis in synovial membrane and, 1410
cytokines, early response genes and, 877
in RA, 492, 1328
rheumatoid synovial adhesion of, to human articular cartilage, 1694
Fibromodulin, in articular cartilage in OA and RA, 660
Fibromyalgia
cerebral blood flow and pain in, 926
cognitive deficit in rheumatic diseases and, 1363
parvovirus B19 infection, chronic fatigue syndrome and, 638
prevalence and characteristics of, 19
sexual abuse and, 161, 229, 235
sleep electroencephalography and amitriptyline in, 1211
in SLE, 872
Fibromyalgia-like symptoms, in SLE, 1475
Fibronectin
antineutrophil cytoplasmic antibodies in mice and, 1375
Arg-Gly-Asp (RGD) peptide, IL-1, chondrocytes, matrix metalloproteinase synthesis and, 1304
EDA-containing, in RA synovium, 678
Fibrosis
cutaneous, in scleroderma in Tsk2 mouse, 1791
interstitial lung, HLA type and, 259
in PM, 437, 690
pulmonary, in SSc, 939, 1024
Fibrous RA, EDA-containing fibronectin in synovium in, 678
Fibula, distal, stress fractures in RA and, 1025
Fibular collateral ligaments, in CPPD synovitis in rabbit OA, 201
52-kd SS-A/Ro molecule, autoepitopes of, 990
Filtration, erythrocytes in rheumatoid vasculitis and, 248
Finger
autoamputation secondary to untreated gouty arthritis, 1241
incidence of OA in, 1134
ischemic, in cutaneous PAN associated with Crohn's disease and atrial myxoma, 1161
lesions, 1161
tendons, in RA, 786
Fingerprinting, DNA, to study autoantibodies in twins with scleroderma, 1845
Finnish Twin Cohort, occurrence of AS in, 381
Fish oil, high-dose, NSAID and, in RA, 1107
5-D-5 keratan sulfate epitope, in knee joint fluid after trauma, 953
5-lipoxygenase, nitric oxide and lipoxin A4 polymorphonuclear neutrophil vascular cytotoxicity and, 768
5`-nucleotidase, in azathioprine toxicity in RA, 142
5` regulatory region, IL-1α polymorphism in JRA and, 221
15-lipoxygenase, nitric oxide and lipoxin A4 polymorphonuclear neutrophil vascular cytotoxicity and, 768
55-kd hyaluronic acid-binding region fragment, stromelysin-cleaved rabbit aggrecan and, 1400
55-kd synovial antigen, antibodies to, in early RA, 1418
Flagellin, Lyme borreliosis and, 565
Flexion, hip, in walking velocity in elderly, 343
Flexor tendon, in RA, 786
Flow cytofluorometry, to study cytokines in JRA, 211, 1531
Flow cytometry
in RA, 485, 649
to study hematology of Felty's syndrome and large granular lymphocyte syndrome, 1252
to study p4 peptide pocket binding and DRB1*0401, 1744
to study peripheral blood neurophils in Behcet's disease, 426
T cell receptor Vβ genes in Sjogren's syndrome and, 1077
two-color, 649
``Flu-like'' symptoms, after chimeric monoclonal anti-CD4 antibody and MTX in RA, 1581
Fluorescence, antineutrophil cytoplasmic antibodies in SLE and, 633
Fluorescence-activated cell sorter analysis
to study antigen-based heteropolymers, 190
to study Arg-Gly-Asp (RGD) peptide, IL-1, chondrocytes, matrix metalloproteinase synthesis and, 1304
to study T cell receptors and RA, 1242
Focal deficit, cognitive deficit in rheumatic diseases and, 1363
Focal lesions, spin-spin relaxation of brain in SLE and, 810
Focal lymphocytic sialadenitis, in Sjogren's syndrome, 869
Focal proliferative glomerulonephritis, renal biopsy in RA and, 242
Folate, plasma, vitamin B6 in rheumatoid cachexia and, 105
Folic acid antagonists, immunosuppressive drugs during pregnancy and, 1722
Followup studies
C4 deficiency in glomerulonephritis, 1333
cognitive deficit in rheumatic diseases and, 1363
of corticosteroids, pulse cyclophosphamide and plasma exchange in polyarteritis nodosa and Churg-Strauss syndrome, 1638
diltiazem in calcinosis, 1646
gastroduodenal injury, NSAID-induced, in children, 1225
guidelines for clinical trials in SSc and, 351
HLA type in MCTD, 259
Followup studies (cont'd)
hyaluronic acid and disease progression in OA, 760
of JRA, 351, 715
juvenile AS, 835
of knee OA in the elderly, 1500
of long-term MTX, 1194
NSAID-induced gastroduodenal injury in children, 1225
of RA, 334, 1120, 1194, 1618, 1630, 1807
of SLE, 267, 274, 1475, 1492
Food and Drug Administration (FDA)
draft guidelines for drugs in JRA clinical trials, 715
Guidelines for Antiinflammatory and Antirheumatic Drugs, 715
guidelines for medical management of OA and, 1535, 1541
Foreign antigens, autoimmune disease induction by microbial pathogens and, 458
Foreign-body granulomatous reactions in total knee prosthesis, 1325
Forgetfulness, cognitive deficit in rheumatic diseases and, 1363
45-kd protein and 45-kd synovial antigens, antibodies to synovial antigens in early RA and, 1418
Fos AP-1 transcription factor, nuclear factor-κ-B in rheumatoid synovium and, 1762
Fractures
hip, 374, 907
pseudoseptic inflammatory knee effusion after, in sickle cell disease, 284
stress, in RA, 1025
vertebral compression, functional disability in PM/DM and, 1218
Framingham OA Study, knee OA in the elderly and, 1500
Free clodronate, macrophages, liposomes and, in rat adjuvant arthritis, 1777
Free radicals
lipoprotein oxidation in SSc and, 1060
oxygen, TGFβ1 in hyaluronan synthesis in synovial lining cells and, 669
Functional ability
in DM, 68, 1218
evaluative laboratory testing and, 1555
in JRA, 715, 1142
in OA, 448, 539, 1535, 1541
in PM, 1218
prevalence and characteristics of fibromyalgia and, 19
in RA, 49, 334, 1120, 1568
Functional Fas antigen, apoptosis and, in RA synoviocytes, 485
Functional joint scores, serum metalloproteinases in RA and, 1031
Fusion protein, IL-2 diphtheria (DAB486IL-2), in refractory RA, 1177
FVDIPEN-COOH, stromelysin-cleaved rabbit aggrecan and, 1400